Drug Profile
P BCMA ALLO1
Alternative Names: CAR T-cell therapies - Janssen/Poseida Therapeutics; P-BCMA-ALLO1; RG-6538Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Janssen Biotech; Transposagen Biopharmaceuticals
- Developer Poseida Therapeutics; Roche
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 13 Mar 2024 P BCMA ALLO1 receives Orphan Drug status for Multiple myeloma (Second-line therapy or greater) in USA
- 10 Dec 2023 Efficacy, adverse event, and pharmacodynamics data from a phase I P-BCMA-ALLO1-001 trial in Multiple myeloma released by Poseida Therapeutics
- 09 Dec 2023 Adverse events data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)